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the tumor microenvironment can be spatially heterogenous, which makes it challenging to fully 
characterize with standard 2D histology-based methods. In this study, we determined the feasibility of 
a CLARITY tissue-processing approach to analyze biopsies from breast cancer patients. Formalin-fixed 
human breast cancer core-needle biopsy specimens, were embedded, lipid-cleared, and multiplexed 
immunostained to identify key biomarkers (pan-cytokeratin, Ki67, CD3). Confocal microscopy was then 
used to image the specimens after refractive index matching. These data sets were then quantitatively 
compared to conventional slide-based FFpe histology. Using CLARItY, the gross and cellular 
morphology of the tissues were well preserved, and high optical transparency was achieved, with the 
exception of fibrotic regions. Specific staining of various cellular and nuclear markers was achieved using 
optimized antibody conditions. Manually determined composite Ki67 scores from the CLARITY datasets 
agreed with histology results. However, the CLARITY datasets (3D) revealed variation in the intra-
tumoral Ki67 expression that was not evident in individual FFPE sections (2D). We further demonstrated 
that archived FFpe clinical specimens can be CLARItY-processed, immunostained, and imaged. In 
short, CLARItY-processed specimens may enable a more accurate, unbiased analysis of tumor samples 
in comparison to conventional slide-based histology, thus allowing for improved visualization of intra-
tumoral heterogeneity.
In the area of tumor biology, technologies are lacking to merge cellular phenotypic information with 
three-dimensional (3D) spatial analysis of tissues. There remains a need for a quantitative multiplexed analysis of 
key biomarkers in cancer specimens, whereby complex spatial patterns of cells, as well as tissue architecture can 
be reproducibly measured in 3D. It has become clear that the heterogeneity within the tumor microenvironment 
(TME) contributes significantly to the development and eventual metastasis of cancer, as well as the response 
and resistance to treatment1. Current technologies utilized for preclinical, diagnostic, prognostic, and predictive 
clinical cancer research are dependent upon two-dimensional (2D) analysis of formalin-fixed paraffin embedded 
(FFPE) tissue sections (5–10 µm). Other technologies, that utilize flow cytometry, real-time polymerase chain 
reaction, or next generation sequencing to analyze tumors, lack the ability to correlate key quantitative informa-
tion while maintaining the architecture and morphology of the TME2.
Recent publications, from small studies, have demonstrated key spatial relationships between T-cell phe-
notypes and key tumor biomarkers in the TME that show prognostic and/or predictive clinical outcomes3. 
Unfortunately, these techniques suffer from small sampling of the tissue when derived from 5-micron thin sec-
tions. However, a 3D volumetric assessment of tumors, even in the case of small tissue sampling, may increase the 
likelihood to determine statistically significant patterns generated by biological processes, as compared to current 
2D microscopy methods. Thus, the ability to analyze intact tissues may facilitate the identification of clinically 
relevant features. Some possible examples, would be a new avenue of pathological grading criteria of larger sam-
ples or identifying key spatial relationships within the TME, potentially yielding powerful predictions that extend 
beyond simple abundance of key biomarkers1.
Furthermore, the ability to observe molecular and structural heterogeneity in a dynamic neoplasm, such as 
cancer, can be crucial for accurate diagnosis, treatment, and predicting recurrence. Understanding the intricacies 
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of both inter-tumor and intra-tumor heterogeneity have become important goals since they have implications on 
identifying reliable prognostic and predictive molecular biomarkers in clinical oncology4–7. In particular, breast 
cancers are known to exhibit a high level of intra-tumor variability for standard biomarkers such as estrogen 
receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), epidermal growth 
factor receptor (EGFR), and the proliferative marker Ki67, which can result in divergent outcomes7.
The last ten years has seen a surge in methods and reagents to aid in whole tissue processing and subsequent 
3D imaging. CLARITY is one novel approach that is innovative in both function and utility, and has been applied 
broadly to the field of neurobiology, primarily as a qualitative tool. The technology enables the formation of a 
hydrogel matrix (HM) by crosslinking biological molecules to a 3D network of hydrophilic polymers, followed 
by lipid clearing to generate a transparent and structurally intact tissue. The tissue then can be labeled with 
macromolecules and imaged without destruction of the tissue8–12. Other tissue clearing methods can generally 
be classified as either an aqueous/hyperhydration (Scale, CUBIC), organic solvent-based (3DISCO, iDISCO, 
uDISCO, BABB, DMSO), or a refractive index (RI) immersion matching (Ce3D, SeeDB, ClearT)13,14. However, 
the CLARITY technique results in maintenance of tissue structural integrity, allowing multiple rounds of staining 
and de-staining, is compatible with endogenous fluorescence and long-term tissue storage, and has been shown 
to be compatible with both active and passive clearing methods8,10,15.
Although the CLARITY technique was originally conceived and applied to the field of neuroscience15–19, its 
usage has extended to other organs10,20–24. Several other groups have modified parameters that affect clearing and 
antibody penetration, such as temperature9,10, HM composition9,10,22,24,25, and clearing reagents10,24,25. Yet, the 
majority of these studies have been performed in non-cancerous tissues with unoptimized antibody conditions, 
which may contribute to insufficient molecular probe penetration resulting in a “sandwich” like staining pattern 
observed in thick tissue10. Furthermore, protein loss associated with lipid clearing is another important unknown 
factor. Previous publications have noted minimal total protein loss by using BCA protein quantification8,9,24. 
However, the matter of specific epitope preservation post-processing remains inconclusive.
It is unknown if the CLARITY method could be properly controlled or standardized for use with a TME 
relevant multiplexed panel of biomarkers in human cancer specimens; however, results from both our lab and 
others have shown early feasibility to perform singleplex, as well as multiplex immunostaining in fresh, fro-
zen, formalin-fixed pre-clinical mouse and human cancer tissues (breast, pancreas, non-small cell lung cancer 
(NSCLC), lymph node) by the CLARITY method10,21,26. Yet, the more applicable question of cross-validation 
to gold standard histopathology techniques remains, and if archived FFPE blocks can be processed successfully 
through the CLARITY technique and yield comparable results to standard 2D thin-section methods.
In this paper we demonstrate the feasibility of multiplex fluorescent immunoassay staining, with an opti-
mized antibody panel, in CLARITY processed tissues. The multiplex panel comprised of three antibodies: 
pan-cytokeratin (pan-CK), Ki67, and CD3 (representative of the cytoplasmic, nuclear, and membrane com-
partments, respectively) was selected. Pan-CK, an abundant and highly-expressed cytoplasmic protein homog-
enously expressed in xenograft tumors, was used as an optimal antigen for preliminary antibody titrations and 
subsequent breast cancer tissue staining. We chose the proliferative marker, Ki67, to represent the nuclear com-
partment, and to serve as a representative marker for manual counting to compare the quantitative analysis of 
3D images to standard 2D method. Ki67 has been found to display variable expression with two prominent 
types of intra-tumoral heterogeneity: an increased tumor edge staining gradient or prevalent Ki67 staining, “hot 
spots”27,28. While multiple sampling and scoring from the different locations of the tissue exists, there is no con-
sensus in methodology for scoring samples across different studies28,29. As such, a nondestructive method might 
be considered a more accurate assessment for markers like Ki67. CD3 is a critical T cell membrane marker and 
has been frequently studied in the immuno-oncology field, and it broadly can measure the tumor infiltrating 
lymphocytes within the TME.
The goal of this small study was to demonstrate that CLARITY-processed specimens may enable a more accu-
rate, unbiased analysis of tumor samples in comparison to conventional slide-based histology. As such, we first 
determined an observed 0.01% limit of detection in CLARITY processed cell pellet model using both manual 
and automated cell counting. We developed optimized antibody conditions to demonstrate specific staining of 
various cellular, membrane, and nuclear markers using CLARITY processed tissues including isotype controls, 
which have not previously been included in previous publications. We then applied the optimized conditions 
to clinical biopsy specimens, incorporated quantitative analysis of the 3D images, and compare them to their 
respective standard 2D images. We expounded our efforts through a comparison of clinical human breast can-
cer patients’ core needle biopsy tissues processed with the CLARITY technique and the standard FFPE block 
method by manual quantification of Ki67 post processing. The overall composite Ki67 manual score obtained 
from CLARITY-processed tissues was concordant with the respective FFPE slide results. This study demonstrated 
that CLARITY is not only compatible with various tissue processing preparations, allowing for prospective and 
retrospective analysis, but is also a powerful technique for the quantitative identification of select biomarkers that 
may identify tumor cell heterogeneity.
Results
A 0.01% limit of detection can be observed in CLARITY processed cell pellets. Given the heter-
ogenous composition of the TME, the ability to detect rare cells within the cell population of a tissue has become 
a key element in assessing disease progression. A “rare event” in flow cytometry is usually defined by a detection 
frequency of 0.01% or lower within a select number of events30. While flow cytometry has several benefits, it is 
also a destructive technique that removes all spatial components of the TME. With these limitations in mind, 
we sought to determine if rare events could be detected with the CLARITY method using an in vitro approach. 
We created a mixed cell pellet model using HEK293-GFP (green fluorescent protein-endogenous expression) 
and SUP-T1 (unlabeled) cells at specific ratios (Fig. 1a). The endogenously expressed GFP signal minimized 
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Figure 1. A 0.01% limit of detection can be observed in CLARITY processed cell pellets. (a) The mixed cell 
pellets ratios generated with HEK293-GFP and SUP-T1 cells. (b) A representative mixed cell pellet imaged 
before clearing and 10 days after clearing under a dissecting microscope. (c) Confocal microscopy (Leica SP8) 
images of the cell pellets at different ratios (25X). Top row: 3D z-stack images, Bottom row: a corresponding 
representative 2D optical section image. The HEK293-GFP cells (green) can be detected in the FOV for all ratio 
groups, including the rare event level of 0.01%. (d) Manual counting of HEK293-GFP (green) was accomplished 
by calculating the ratio of positive GFP cells/total DAPI (blue) cells (optical sections were used for manual 
counting, n ≥ 5 for each sample). Statistics were calculated by Microsoft Excel and GraphPad Prism 7.0. (e) The 
automated analysis and quantification of the GFP positive cell pellets was performed using a spot detection 
strategy generated with Imaris 9.1.2 software.
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any bias and variables associated with immunostaining. All of the cell pellets were lipid-cleared in about 10–12 
days (Fig. 1b). As shown in Fig. 1c, the fluorescent green signal of the HEK293-GFP cells was bright and easily 
detected in the cell pellet. This was confirmed with multiple fields of view (FOVs) for each group. Assessment of 
the cell pellet ratio accuracy was performed through a manual count of GFP positive cells using multiple indi-
vidual optical sections, at least 50 µm apart in Z direction. With the exception of the 0.01% “rare event” group, all 
the ratios from 20% to 0.1% could be manually counted, and the GFP/SUPT1 cell ratio percentage matched the 
original cell preparation ratio (Fig. 1d). The 0.01% cell ratio demonstrated few positive GFP cells over the entire 
FOV thickness, and thus not all the optical sections had positive GFP cells to count. As a result, manual counting 
of the 0.01% group resulted in a higher-than-average false negative or false positive result. While it is possible to 
count the total number of “rare” GFP positive cells in the 3D FOV image, a manual method to quantify the total 
number of cells in a particular FOV is extremely difficult and taxing due to the inability to clearly track cells that 
extend into more than one optical section.
In fact, this specific concern with manual counting of the 0.01% group, underscored the necessity for an auto-
mated 3D image analysis and individual event segmentation that could not only eliminate duplicate cell counting, 
but also expedite the cell counting process. A preliminary experiment was employed on the same GFP cell pellet 
series to establish feasibility for automated cell counting. One FOV, defined as the entire imaged z-stack from 
each cell pellet, was utilized for the preliminary automated cell count. The spot feature in the Imaris software 
was activated, and parameters were established to distinguish the two different cell sizes of the HEK293 and 
SUP-T1 cell lines for the most accurate count of total cell nuclei. Since only the HEK293 cells expressed GFP, the 
parameters for GFP signal detection were based on a single cell size. A representative example of the imaging 
workflow is shown in Fig. 1e. The software generated a GFP positive cell count (green channel) and a total cell 
count based on the blue channel (DAPI), and the HEK-GFP + percentage was subsequently determined (Fig. 1e). 
Overall, we were able to establish feasibility for an automated counting workflow with a final count that was not 
significantly different from the manual count; however, at the lower extremes of the cell ratio the small variations 
appeared to be more impactful. A more comprehensive analysis employing multiple FOVs, similar to the manual 
counting approach, would be extremely beneficial to determine the consistency and standard deviation of our 
methodology.
establishment of an optimal antibody concentration for immunostaining CLARItY processed 
tissue. In traditional thin-section immunohistochemical (IHC) staining, antibodies are applied directly onto 
5-µm thick tissues and typically incubated for 1–24 hours with minimal problems. However, when immunos-
taining thicker tissue sections (>100 µm), antibody penetration problems, resulting in a “sandwiched” staining 
pattern, are frequently observed10. There may be several reasons to explain this staining pattern, such as unopti-
mized antibody concentration or incubation time due to the slow passive diffusion of antibodies into the center 
of thick tissue sections. To this end, there was a need to establish a specific approach for immunostaining thicker 
tissues that would result in saturated and optimal antibody binding. To address this matter, we utilized two dif-
ferent types of tissues (MCF-7 xenograft tumors and hyperplasia human tonsils) and three different antibodies 
(pan-CK, Ki67, and CD3) for titration experiments. Pan-CK(AE1/AE3)-AF488 (a directly conjugated antibody) 
could bind homogenously to the epitopes in the MCF-7 tissues and serve as an ideal marker for an initial XZ scan 
by a confocal microscope. The samples’ XZ scans were quickly analyzed daily to obtain the depth of antibody 
penetration in relation to antibody concentration and incubation time (Supplemental Fig. S1). For the pan-CK 
antibody titration with MCF-7 xenografts, four different dilutions (1:5, 1:10, 1:20, 1:50) were tested and imaged 
daily for 10 days (Supplemental Fig. S1a). These initial data demonstrated a clear correlation between antibody 
concentration, penetration depth, and incubation time. The signal was found to reach maximum saturation on 
day 5, with no significant signal improvement observed with prolonged incubation or replenishment of the pri-
mary antibody (Supplemental Fig. S1b,c). An incubation period of five days was then applied to the remaining 
antibody titrations for Ki67 and CD3 in the human tonsil tissue, where the observed expression pattern and 
location was particularly specific.
The human tonsil tissues, embedded in an A4B4P4 HM, were biopsy-punched to an equal size 
(3 mm × 3 mm × 0.5 mm) and cleared for approximately 10 days (Fig. 2a). The primary antibodies were titrated 
at the following dilutions: Ki67 (1:20, 1:100, 1:1000) and CD3 (1:10, 1:50, 1:500). Following immunostaining, 
each test group was then imaged using a z-stack scan (step size 2 µm) taken from the germinal center region for 
comparative analysis (Fig. 2b). We found that a concentration of 1:100 and 1:50 for the Ki67 and CD3 antibodies, 
respectively, demonstrated the optimal titration with a low background, high signal-to-noise (S/N) staining, and 
complete antibody penetration. At the lowest concentration, Ki67 (1:1000) and CD3 (1:500), both had a weak 
signal throughout the entire tissue, indicating an insufficient antibody concentration for the amount of epitope 
present in the tissue. On the other hand, tissues immunostained at the highest concentrations, Ki67 (1:20) and 
CD3 (1:10), showed a low S/N, demonstrated by high background and non-specific staining, particularly on the 
tissue surface. We further compared the mean fluorescence intensity (MFI) of the antibody concentrations, Ki67 
(1:100) and CD3 (1:50) to their respective isotype controls using ImageJ. Optical sections, spaced 40 µm apart in 
the Z direction were selected for analysis, and both antibodies demonstrated consistent MFI signals throughout 
the thickness of the tissue (Fig. 2c).
The incorporation of the CLARITY process on previously fixed clinical core needle biopsy sam-
ples preserves the tumor microenvironment. We expanded our studies into previously formalin-fixed 
human breast cancer core needle biopsy tissue from patients that underwent excisional surgery. As previously 
mentioned, the samples were collected, sectioned into mirrored pieces for subsequent A4B4P4 HM-embedding 
(500 µm sectioned tissue), and FFPE block tissue preparation (5 µm sectioned tissue) followed by immunos-
taining and analysis (Fig. 3a). The samples not only remained intact, but cellular morphology was preserved 
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suggesting that a pre-fixation step following by hydrogel embedding and immunostaining could be a feasible 
workflow.
The average lipid-clearing time for the breast cancer tissues ranged from 5–14 days depending on the var-
ying tissue compositions of individual samples. The majority of the samples reached optical transparency; 
however, some specimens contained fibrotic regions and retained some opacity (Fig. 3b). The samples demon-
strated specific staining of various cellular and nuclear markers. Antibody signals, from all four laser channels, 
were observed throughout the whole tissue thickness using laser-gain adjustment through the z-stack, with no 
observed “sandwich” staining pattern (Fig. 3c, Supplemental Videos S1–S3), confirming full sample penetration. 
A sample of individual optical sections, from tumor #8, were selected to further demonstrate the specific subcel-
lular staining observed throughout these thick tissue sections.
Figure 2. Establishment of an optimal antibody concentration for HM embedded tissues. (a) Images of human 
tonsil sections embedded in an A4B4P4 HM (3 mm × 3 mm × 0.5 mm) before and after clearing, 10 days. (b) 
Confocal z-stack imaging of antibody titrations in tonsil tissues (25X), Ki67 (yellow, left), CD3 (red, right), 
and DAPI (blue). For each antibody titration, three different concentrations were used: Ki67 (1:20, 1:100, 
1:1000), CD3 (1:10, 1:50, 1:500), DAPI (1:500), and displayed in 3D: XY axes view (left), XZ axes view (middle), 
and a respective 2D optical slice (right). The images of corresponding isotype controls stained at the optimal 
concentrations are showed in the last row. (c) The mean fluorescence intensity (MFI) of Ki67 or CD3 and their 
isotypes were quantified using Image J at different tissue depths. Each optical section has multiple selected areas 
(n = 5) used for MFI quantification and the images were plotted with mean and standard deviation values by 
GraphPad Prism 7.0.
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CLARITY allows for an unbiased pathology score based on Ki67 expression. To substantiate that 
the antibody signal detected was representative of its expression level, we utilized a traditional method to score 
Ki67 expression in our thick HM-embedded tissue images in comparison to the gold standard FFPE. Using the 
previously mentioned FFPE thin sectioned tissues, at least 10 images from five individual FFPE slides (50 µm 
apart) were chosen to score. Additionally, optical sections from the z-stacks of the thick tissue sections were 
selected in a similar fashion to score (Fig. 4a). An example of breast tumor #7 was used to demonstrate the 
approach. Based on the H&E images, tumor #7 was determined to be an invasive ductal carcinoma with some 
regions appearing to be adjacent normal tissue within the same block (Fig. 4b). Due to its heavy fibrotic nature, 
only partial tissue clearing was achieved (Fig. 4b). The stained FFPE slides and thick tissue sections were both 
imaged with a confocal microscope (25x objective) and showed specific staining of Ki67, pan-CK, and CD3 with 
the high resolution required for pathology scoring (Fig. 4c,d, Supplemental Video S2). The comparison of the 
overall Ki67 pathology scoring data between the 3D thick tissue images and 2D FFPE images from multiple sam-
ples revealed there was no statistical difference between the two tissue processing methods (Fig. 4e). However, it 
is worth mentioning that certain tumor tissues, such as tumors #3 and #8, were found to be more heterogenous 
than the others (Fig. 4f). Despite a comparable cumulative mean Ki67 score between multiple thin FFPE slides 
and optical sections from the thick HM-embedded tissue (~30–60%), we found using one randomly chosen slide 
from the FFPE slide group would not be a true representative of the overall molecular expression level. However, 
the advantage of employing the non-destructive CLARITY method with thick tumor tissues, is the ability to 
Figure 3. The incorporation of the CLARITY process on previously fixed breast cancer core needle biopsy 
samples preserves the tumor microenvironment. (a) A schematic workflow diagram of tissue processing, 
clearing, immunostaining, and imaging for the pre-fixed clinical biopsy samples. (b) Gross image of tumor 
biopsy tissue #8 before vibratome sectioning (2 mm × 1.5 mm), after sectioning (0.5 mm thickness), and post 
lipid clearing. Representative images from the FFPE corresponding tissue were also H&E stained and displayed 
(10x, 40x). (c) Confocal microscope imaging of breast cancer tumor #8 (25X). The total 3D volume is visualized 
in individual and merged channels (left group), and 2D optical section images (25X, right group) demonstrate 
the staining uniformity that is maintained and increasing imaging depths. The breast tissue was immunostained 
with antibodies against pan-CK (green), Ki67 (yellow), CD3 (red), and a DAPI nuclear counterstain (blue). 
Images were visualized by Imaris Version 9.1.2.
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evaluate an entire tumor and obtain an unbiased Ki67 pathology score that truly reflects the overall molecular 
expression levels.
CLARItY processed tissues can be incorporated for retrospective analysis of FFpe tis-
sues. CLARITY has already demonstrated compatibility with multiple pre-clinical and clinical tissue types 
preserved in a variety of ways (fresh, frozen, and formalin-fixed); however, the applicability of CLARITY to 
Figure 4. CLARITY allows for an unbiased pathology score based on Ki67 expression. (a) Schematic diagram 
depicting the methodology and optical slice selection used to compare individual 2D FFPE sections (5 µm, 
left) to the corresponding 3D thick section (500 µm, right) for Ki67 scoring. Blind scoring was done by two 
independent pathology professionals and results were analyzed with GraphPad Prism 7.0. (b) Images of 
tumor tissue #7 before sectioning, after sectioning, post clearing, and the corresponding FFPE H&E staining 
of the tissue (10x, 40x). Representative confocal images of tumor #7 (c) 2D FFPE immunofluorescence 
staining (25X) and (d) 3D volumetric (top row) and optical slices (bottom row) HM embedded thick tissue 
immunofluorescence staining (25X). Blue: DAPI, Green: pan-CK, Yellow: Ki67, Red: CD3, 25X (e) A 
comparison of Ki67 positive ratio (Ki67 positive epithelial/total epithelial) in corresponding FFPE thin sections 
and HM thick sections (p-values as listed, unpaired t test) in biopsy samples. (f) Representative images of tumor 
#8 with heterogenous expression of Ki67 in FFPE 2D thin sections from different sections (25X) demonstrating 
differing levels of Ki67 positive rates.
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archived specimens has not been well studied. We investigated whether archived tissues from FFPE blocks could 
be processed by the CLARITY method, immunostained, and manually quantified. Feasibility was first demon-
strated using normal mouse kidneys and MCF-7 xenograft tumors taken from FFPE blocks. The paraffin blocks 
were melted, the tissues were deparaffinized, and embedded with an A4B4P4 HM solution (Fig. 5a). The kidneys 
and xenograft tumors were then cut into 200 µm thick slices that were cleared, immunostained, and imaged to 
detect multiple biomarkers (α-SMA, lectin, pan-CK and Ki67) (Supplemental Fig. S2).
Additional confirmation of our findings was done by utilizing clinical FFPE samples. We used a portion of the 
previously described FFPE breast cancer core needle biopsy tissues (specifically tumors #6, #7, #8) to deparaffin-
ize, HM-embed, and immunostain. These FFPE-to-HM converted samples were then compared to their respec-
tive standard FFPE 2D thin sections after they were scored for Ki67 expression. All of these tissues maintained 
their structure during the workflow process, and the lipid-clearing duration was not affected by the previous 
FFPE sample preservation (Fig. 5b). We were able to confirm our initial findings, reflected through robust immu-
nostaining with antibodies against pan-CK, Ki67, and CD3 with a DAPI counterstain (Fig. 5c, Supplemental 
Video S4). Finally, we performed an analysis on the Ki67 score generated for both the FFPE-to-HM tumors and 
their mirror-faced FFPE 2D thin section respective counterparts (Fig. 5d). In general, the Ki67 expression for 
both preparations were found to be equivalent, which indicated CLARITY can be compatible with archived FFPE 
tissues. Tumors 6 and 7 both had minimal intra-tumor variation in Ki67 expression (approximately 0–10%); 
however, the most impactful result from these samples was highlighted in tumor #8, which was found to have a 
wide-range in expression of Ki67 positive cells (~30–60%).
Figure 5. CLARITY processed tissues can be incorporated for retrospective analysis of FFPE tissues. (a) A 
general workflow diagram of deparaffinization and subsequent tissue clearing and immunostaining utilized for 
archived FFPE blocks (b) Deparaffinized FFPE tumors #6, #7, and #8 (Indiana breast cancer core biopsy tissue) 
were re-embedded into an A4B4P0 HM solution followed by lipid clearing. The images show the tissues both 
before and five days after lipid clearing. (c) Confocal images of tumor #7 at 25X (Blue: DAPI, Green: pan-CK, 
Yellow: Ki67, Red: CD3). Top row: 3D volumetric images viewed from both the XY axes and XZ axes. Bottom 
row: Individual 2D optical section from the 3D view from increasing depths. In certain optical sections, the 
Ki67 positive epithelial cells and infiltrating CD3 positive T cells can be observed, denoted by arrows. (d) A 
comparison of Ki67 positive ratio (Ki67 positive epithelial cells/total epithelial cells) scores between respective 
converted FFPE to HM and FFPE thin sections (unpaired t test, p-value as listed).
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Discussion
The practical limitations of conventional histology include labor-intensive and imprecise sample sectioning, 
reconstruction, and quantification of biomarkers31,32. Furthermore, the majority of clinical IHC testing involves 
single analyte detection visualized in a small number of representative samples, hindering the ability to under-
stand inherent spatial heterogeneity in tumors33. In addition, there can be variability in an FDA approved or 
laboratory derived tests depending on the antibody/assay used, which can lead to further discrepancies34,35. To 
address these needs, newer methods that employ multiplex immunofluorescence have been applied to 2D FFPE 
tissue to partially overcome the single analyte approach, and to add spatial and phenotypic information36,37. While 
advancing research applications in the field of immuno-oncology, these methods are still based on a small sam-
pling of the tumor. CLARITY could become a technique that can address both the spatial heterogeneity of intact 
tumors and multiplex staining directly, holding the unique advantage in immune microenvironment research. 
Furthermore, optimization of key parameters could lead to future quantitative spatial relationships that are clin-
ically meaningful that may overcome the limitations of 2D thin section techniques.
Unlike the lipid-rich and homogeneous structure of the mouse brain, solid tumors often have an abundance 
of fibrotic tissue and a heterogeneous composition, which can make a visual assessment of tissue clearing difficult 
between individual samples. However, there remains a need for multiplexed analysis of key biomarkers in cancer 
pathological specimens, whereby complex spatial patterns of cells, as well as tissue architecture can be reproduc-
ibly measured. A standardized, reproducible tissue processing method that allows the accurate identification, as 
well as quantification of key biomarkers and spatial relationships within the TME in 3D for research and clinical 
applications is paramount. As a result of all these unique factors and requirements, a comprehensive optimization 
of key aspects of the CLARITY technique is necessary to achieve these goals.
While previous publications have addressed multiple ways to improve antibody penetration and staining 
quality through either optimization of the HM formulation, tissue fixation9,10,24, or by applying active antibody 
infusion methods22,24,38, we sought to understand whether full penetration of select molecular probes could be 
achieved using an antibody titration approach. In the titration study, we decided to utilize a tissue model given 
the divergent antibody penetration dynamics between cell pellets, which lacks an extracellular matrix compo-
nent, and structurally intact tissues. Murine xenograft tumor tissue, although moderately different from human 
tumor tissues, can serve as a robust model to study antibody titration/penetration for tumor markers. Contrary 
to typical 2D antibody titration, the antibody penetration necessary for thicker HM-embedded tissues requires 
analysis in the axial direction as well. Thus, an ‘XZ’ microscopic scan was required to assess penetration in the Z 
axis, followed by a calculation of the S/N ratio. The primary objective was to establish the appropriate antibody 
concentration range that exhibited both a high S/N ratio and maximum penetration and saturation of the thick 
HM-embedded sections. The more complex and heterogenous human tonsil was deemed more appropriate to 
titrate the remaining antigens, Ki67 and CD3, which required a detailed subcellular and cellular analysis, respec-
tively, on individual ‘XY’ optical sections prior to Z axis analysis. We opted to focus on the originally published 
CLARITY HM formulation8 to substantiate the necessity of proper antibody titration for thick tissue immunos-
taining penetration. Furthermore, we also included isotype control groups, with matched characteristics (species, 
class, type) to their respective primary antibodies, to provide a more accurate negative control in thick tissue 
immunostaining which has been neglected in previous publications.
As part of this study, we set out to better understand if the CLARITY technique could aid in the detection of 
rare events in a 3D volume. While we were able to correlate the data between the theoretical and actual groups, 
especially in “frequent events” (0.1–20% GFP samples), we encountered some difficulties in providing similar 
evidence for the 0.01% “rare event” group. Manual counting can be a laborious and time-consuming approach, 
particularly in the case of rare event counting over a 3D volume of tissue39. In contrast, digital image analysis can 
be a quick, non-labor-intensive approach; however, due to the general parameters established for counting, it can 
result in increased false positives until the system is optimized for the particular data set of interest. Although 
there were some inherent variables in cell preparation and cell counting, we did demonstrate an ability to detect 
true positive rare events using an endogenous fluorescence marker within a volume of tissue. Being able to detect 
rare events, while maintaining the spatial structure of the tissue has implications for understanding the complex 
biology of a heterogeneous system more accurately then 2D thin section FFPE methods.
Further examination of key protein measurements using CLARITY methods was determined using multi-
plex immunostaining and a manually derived Ki67 count in human breast cancer specimens. For comparison to 
gold standard methods, we utilized a composite of 2D FFPE thin section specimens from another portion of the 
patient’s core biopsy. In our studies, we demonstrated the potential for differential expression of Ki67 expression 
between thick CLARITY processed and serial thin FFPE prepared tissue sections. The concordant results indi-
cated that the clinical samples processed by the CLARITY method, had similar quantitative results compared 
to the gold standard methodology when compared as a composite. Importantly, significant epitope loss was not 
observed when compared with standard 2D thin section results. Additional validation studies with a large dataset 
will be required to confirm our findings. Interestingly, the results from a small set of archived FFPE tissue samples 
from the same patients that were subsequently processed by the CLARITY method were also concordant with 
tissues that were prepared by traditional FFPE techniques. This suggests that in addition to the CLARITY method 
being compatible with fresh, frozen, and fixed tissue, it is also compatible with archived FFPE tissue. This opens 
up the ability to process archived FFPE samples and compare the results with clinical outcome data.
Understanding the intricacies of both inter-tumor and intra-tumor heterogeneity have become an impor-
tant concern in establishing prognostic and predictive molecular biomarkers in clinical oncology4–7. There are 
currently very few clinical biomarkers that correlate with clinical outcome and confounding factors such as 
intra-tumor heterogeneity can impact the accuracy of these biomarkers4,6. The need for more effective prognos-
tic and predictive biomarkers for immuno-oncology drugs is growing rapidly, as response rates continue in the 
10–30% range and the extent of possible drugs, including combination therapy, grows at an accelerating pace40. 
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Sampling bias can result from sparse observation of a single FFPE slide, which can impact the reliability of the 
scoring analysis. Therefore, 3D techniques, such as CLARITY, clearly hold the advantages of enabling a more 
accurate and quantitative analysis of tumor samples, particularly for heterogeneous samples.
Although non-destructive tissue techniques, such as CLARITY, have the ability to preserve structural integrity 
of the tissue and reveal biomarker relationships in 3D, limitations still exist. The major limitation is the length of 
time it takes to clear and immunostain tissues. Lengthy tissue processing time frames limit the turnaround time 
of data to be a viable technology for use in drug development and clinical research applications in the future. 
Limitations also exist with the commercially available image analysis software, and to that end, more sophisti-
cated and applicable software must be developed to handle large datasets, as well as the development of machine 
learning algorithms to handle feature extraction and meaningful 3D spatial relationships in the TME. To this end, 
automated and expedited ways to process tissue in 3D as well as automated imaging is critical for this technique 
to be useful for both clinical research applications as well as integration into typical clinical workflow paradigms.
In conclusion, our study demonstrated that CLARITY prepared tissues are compatible with various processed 
clinical tissues, thus allowing future prospective and retrospective analyses. It is a powerful technique to quan-
titatively identify biomarkers in the TME using a manual scoring approach. This manuscript would be the first 
example in CLARITY processed tissue for antibody titrations and optimization, in conjunction with a compara-
tive isotype control. Based on these studies, the ability to accurately quantify the markers in CLARITY processed 
tissue holds great promise that the TME can be more accurately evaluated with larger volumes of intact tissue. The 
development of automated image analysis methods that can be incorporated into the 3D analysis of preclinical 
and clinical tissue is crucial as well.
Methods
Animals and human specimens. Normal murine tissues and xenograft model MCF-7 tumors were gen-
erated and collected in the Molecular Medicine Research Institute (MMRI, Sunnyvale, CA) animal facility based 
on guidelines of the National Institutes of Health (NIH) and approved by the Institutional Animal Care and Use 
Committee (IACUC, protocol #16-002). Approximately 107 MCF-7 (ATCC HTB-22, Manassas, VA) cells were 
utilized to inoculate NOD scid gamma female mice (6–8 weeks, #005557, The Jackson Laboratory, Bar Harbor, 
ME) to generate tumors.
Human de-identified breast cancer core needle tissues from excision biopsies (n = 6) were collected from the 
Indiana University School of Medicine. All protocols were reviewed and approved by the Institutional Review 
Board (IRB) of Indiana University. Samples and clinical records were anonymized prior to access by the authors 
and linked with a numerical identifier. The requirement for informed consent was waived by the IRB. Tissues 
were pre-fixed in 10% neutral buffered formalin for less than 24 hours and shipped in RPMI-1640 media. Upon 
arrival, individual tissues were sectioned as follows: one-half was embedded into a HM for thick section (500 µm) 
processing, one-quarter (a “mirror face” to the HM-thick section) piece was paraffin-embedded using a Tissue 
Tek VIP 1000 processor for subsequent thin section (5 µm) analysis, and the remaining one-quarter of the tissue 
was stored at −80 °C for future use. Fresh frozen human de-identified hyperplastic tonsil tissue was obtained 
commercially from Asterand (Detroit, MI).
Cell pellet preparation and processing. Cell pellet mixtures were generated by using human embryotic 
kidney cells 293-green fluorescence protein (HEK293-GFP) stable cells (#SC001, GenTarget, Inc., San Diego, 
CA) and SUP-T1 (#CRL-1942, ATCC, Manassas, VA). The cell pellets were embedded into the classic CLARITY 
A4B4P4 HM formulation for 48 hours at 4 °C. Each cell pellet contained approximately 5 × 106 cells, with a cell 
pellet size measuring 3 mm × 3 mm × 2 mm. The A4B4P4 hydrogel, which has been previously described was 
composed of 4% acrylamide (vol/vol), 0.05% bis-acrylamide (vol/vol), 4% PFA (vol/vol), and 0.25% VA-044 ini-
tiator (wt/vol) in phosphate-buffered saline (PBS)9. The cell pellets were degassed with a nitrogen-flush and vac-
uum chamber for 10 minutes at room temperature (RT) followed by polymerization at 37 °C for three hours. After 
removing the excess gel, the cell pellets were submerged into a clearing solution containing 8% sodium dodecyl 
sulfate (SDS, vol/vol) and sodium borate buffer (200 mM, pH 8.5), and placed in a shaking incubator at 45 °C for 
lipid clearing until they reached optical transparency. The pellets were removed from the SDS/borate clearing 
solution, rinsed 3–4 times with PBST (0.1% Triton X-100 (vol/vol) in PBS) over a 24-hour period, and stained 
with DAPI (#62248 Thermo Fisher Scientific, 1 mg/ml, 1:200, Waltham, MA) for three days at 37 °C. Finally, the 
pellets were washed with PBST 4–5 times overnight, before submersion into RapiClear CS (#RCC, S002, Sunjin 
Labs, Taiwan), a refractive index (RI) matching solution. RI matched cell pellets were mounted onto a glass cov-
erslip (22 × 30 mm, #72200-20 Electron Microscopy Sciences, Hatfield, VA) and imaged in a z-stack with a Leica 
SP8 confocal microscope system (Leica Microsystems, Buffalo Grove, IL) using a 25X, 0.95NA water immersion 
objective (5 µm z-step size, 1024 × 1024 resolution). The cell pellets were excited by both the 405 nm and 488 nm 
laser lines and multiple fields of view (FOVs) were imaged. The images were reconstructed in 3D and analyzed 
using Imaris 9.1.2 software (Bitplane, Zurich, Switzerland). For manual cell counting, the GFP positive cells and 
total cells, based on the DAPI staining, were counted from at least five different optical sections (at least 50 µm 
apart, along the z-axis, to avoid duplicate single cell counting) and data were input into Excel and GraphPad 
Prism 7.0 for statistical analysis.
tonsil tissue processing and antibody titration. The tonsil tissue was embedded into an A4B4P4 
hydrogel and cleared as described previously for the cell pellets. Ki67 (1:20, 1:100, 1:1000) and CD3 (1:10, 1:50, 
1:500) antibodies were applied at 37 °C for five days followed by the Alexa-Fluor secondary antibodies incubated 
under the same conditions. After washing with PBST and RI matching, images were taken with the Leica SP8 con-
focal microscope using a 25X, 0.95NA water immersion objective (3 µm z-step size, 2048 × 2048 resolution, with 
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laser adjustment (1% to 20%) to account for light scattering at increased imaging depth). Tissues immunostained 
with either specific biomarkers or with isotype controls were imaged with exactly the same settings.
Pre-fixed human breast cancer core needle biopsy tissue processing. Upon arrival, the pre-
fixed breast cancer core needle biopsy tissues (2 mm × 2 mm × 1 cm) were rinsed with PBS once, sectioned into 
“mirror-faced” halves with one-half placed into the A4B4P4 HM formulation for 48 hours at 4 °C. Then the tissues 
were degassed and polymerized as previously described for the cell pellets. Afterward, the tissues were embedded 
in a 4% agarose mold, sectioned into 200 µm or 500 µm thick sections with the Leica VT1200S vibratome (Leica 
Biosystems, Wetzlar, Germany), and cleared as previously described for the cell pellets. Briefly, the samples were 
blocked (10% normal goat serum, 3% bovine serum albumin, 0.1% Triton X-100, 0.01% sodium azide (wt/vol), 
PBS) overnight at RT, incubated with primary antibodies diluted in PBST at 37 °C for five days, washed five times 
with PBST for one hour each, and incubated with Alexa Fluor-conjugated secondary antibodies diluted in PBST 
at 37 °C for five days. After a PBST wash, the samples were RI matched, and imaged. The antibodies and dilutions 
used in this study can be found in Table 1. The samples were RI matched and imaged with a Leica SP8 confocal 
microscope using a 25X, 0.95NA water immersion objective (3 µm z-step size, 2048 × 2048 resolution).
CLARItY-processed FFpe tissue preparation. FFPE tissues (normal mouse kidneys, MCF-7 xenograft 
tumors, and human breast cancer biopsies) were deparaffinized in xylene (3 exchanges: 2x, 1 hour each, and 
1X- overnight) at RT, rehydrated in serial ethanol (EtOH) solutions (100% EtOH: 2x, 30 mins each; 95% EtOH: 
30 mins; 70% EtOH: 30 mins; 50% EtOH: 30 mins), rinsed with cold tap water, and stored in a hydrated condition. 
The tissues were embedded into an A4B4P4 HM (mouse kidneys and MCF-7 xenograft tumors) or an A4B4P0 
(pre-fixed human breast tumor, 4% acrylamide and 0.05% bis-acrylamide) at 4 °C for 48 hours and vibratome 
sectioned into 200 µm and 500 µm thick sections using a 4% agarose mold. The sectioned tissues were processed 
for lipid-clearing as described previously. Antibody dilutions are listed in Table 1.
FFpe thin section tissue processing, immunostaining and H&e staining. FFPE thin sections 
(5 µm) were deparaffinized in xylene (2X, 10 min each) and rehydrated in an EtOH/water gradient series (100% 
EtOH - 10 min, 95% EtOH - 5 min, 70% EtOH - 5 min, 50% EtOH - 5 min). The rehydrated slides were briefly 
washed with water and kept hydrated. Antigen retrieval was performed using Diva Decloaker (#DV2004MX, 
Biocare Medical, Pacheco, CA), which included boiling the samples for 15 mins followed by cooling to RT 
(~10 minutes). The slides were then washed three times in PBS (10 mins each) and treated with Sudan Black B 
(#199664, Sigma-Aldrich, St. Louis, MO) for 1.5 hours, to quench autofluorescence. After washing with PBS three 
times (10 mins each), the slides were blocked with serum free protein block (#X0909, Dako/Agilent, Carpinteria, 
CA) for one hour at RT. Primary antibodies were incubated overnight at 4 °C, washed three times (10 mins each), 
followed by a secondary antibody incubation for one hour at RT. See Table 1 for the specific antibody dilution 
used. DAPI was applied as a nuclear counterstain at a dilution of 1:500 (500 µg/ml). The slides were mounted with 
Fluoroshield histology mounting medium (F6182, Sigma Aldrich, St. Louis, MO), covered with a glass coverslip 
(#48404-452, VWR, Radnor, PA), sealed with clear nail polish, and stored in the dark at 4 °C until imaged. For 
each breast cancer tissue FFPE block, at least one thin section (5 µm) was stained with hematoxylin and eosin 
Ab name Clone Dilutions Vendor Catalogue # Stock concentration
Pre-fixed and FFPE processed human breast cancer biopsy tissue staining (500 µm)
Pan-CK-AF488 AE1/AE3 1:10 Thermo Fisher Scientific, Waltham, MA #53-9003-82 0.5 mg/ml
Ki67 polyclonal 1:100 Abcam, Cambridge, UK #ab15580 1.0 mg/ml
CD3 LN10 1:50 Leica, Wetzlar, Germany #ACI3152C 32 µg/ml
Mouse IgG1-AF488 isotype control MOPC-21 1:4 Biolegend, San Diego, CA #400129 0.2 mg/ml
Rabbit IgG isotype control polyclonal 1:20 Abcam, Cambridge, UK #ab27478 0.2 mg/ml
Goat-anti-mouse AF647 polyclonal 1:200 Abcam, Cambridge, UK #ab150115 1.96 mg/ml
Goat-anti-rabbit AF568 polyclonal 1:200 Abcam, Cambridge, UK #ab175695 2 mg/ml
FFPE processed mouse kidney and xenograft tissue staining (500 µm)
Αlpha-smooth muscle actin (α-SMA)-FITC polyclonal 1:100 Abcam, Cambridge, UK #ab188498 1 mg/ml
Lectin-Texas Red N/A 1:1000 Vector labs, Burlingame, CA #TL-1176 1 mg/ml
Human breast cancer FFPE thin section staining (5 µm)
Pan-CK-AF488 AE1/AE3 1:500 Thermo Fisher Scientific, Waltham, MA #53-9003-82 0.5 mg/ml
Ki67 polyclonal 1:400 Abcam, Cambridge, UK #ab15580 1.0 mg/ml
CD3 LN10 1:500 Leica, Wetzlar, Germany #ACI3152C 32 µg/ml
Mouse IgG1-AF488 isotype control MOPC-21 1:200 Biolegend, San Diego, CA #400129 0.2 mg/ml
Rabbit IgG isotype control polyclonal 1:80 Abcam, Cambridge, UK #ab27478 0.2 mg/ml
Goat-anti-mouse AF647 polyclonal 1:500 Abcam, Cambridge, UK #ab150115 1.96 mg/ml
Goat-anti-rabbit AF568 polyclonal 1:500 Abcam, Cambridge, UK #ab175695 2 mg/ml
Table 1. Antibodies and dilutions employed in the noted studies.
1 2Scientific RepoRts |          (2019) 9:5624  | https://doi.org/10.1038/s41598-019-41957-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
(H&E) (Hematoxylin, #HHS128-4L; Eosin Y, #HT110316, Sigma, St. Louis, MO) and observed under a light 
microscope to verify the quality of the tissue.
Pathology score and comparison on 2D FFPE thin section images and 3D CLARITY processed 
thick section images. Ki67 positive epithelial ratios were obtained for both 2D FFPE thin section images 
and optical slides from 3D CLARITY processed thick tissue. For the CLARITY processed thick sections, five 
optical sections from the 3D z-stack (50 µm apart, two FOVs, 10 total images) were taken for quantification. 
Ratios from the 2D FFPE thin sections used five slides (~50 µm apart), from each individual tumor for analysis. 
For example, slides #11, #21, #31, #41, #51 from tumor #7 and slide #2 (isotype control) were chosen to score. Two 
different FOVs from these six slides were chosen to score (total of 12 images). The ratio of Ki67 positive signal 
was calculated by the number of Ki67 positive epithelial cells/the total number of epithelial cells (at least 500 cells 
were counted per view, Fig. 4a)29,41.
statistics. The group mean, standard deviation (SD), and statistical significance were calculated using 
Microsoft Excel and GraphPad Prism 7.0. The p-value was calculated based on the unpaired t-test.
ethics approval and consent to participate. Human de-identified breast cancer core needle tissues from 
excision biopsies were collected from the Indiana University School of Medicine in accordance with guidelines 
from NIH and approved by the Institutional Review Board (IRB)
Normal murine tissues and xenograft model MCF-7 tumors were generated and collected in the Molecular 
Medicine Research Institute (MMRI, Sunnyvale, CA) animal facility based on guidelines of the National Institutes 
of Health (NIH) and approved by the Institutional Animal Care and Use Committee (IACUC).
Data Availability
The datasets used and/or analyzed within the current study are available from the corresponding author upon 
reasonable request.
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